Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT07767864
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Participants will receive bimekizumab 320 mg administered subcutaneously every 2 weeks for the first 16 weeks, followed by 320 mg every 4 weeks through Week 24

Study Details

The purpose of the study is to learn more about an experimental drug bimekizumab that may be helpful for Pyoderma Gangrenosum (PG). Bimekizumab will be referred to as the study drug throughout this form. The investigators are hoping to find out if bimekizumab helps in healing PG wounds. The study drug is experimental. It has been approved by the FDA for use in adults with psoriatic conditions but not for Pyoderma Gangrenosum (PG).

Key Dates

First listed
Aug 17, 2026
Start date
Sep 1, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Will receive study drug

Primary Outcome Measure

Proportion of participants that achieve a PGA score of ≤ 1 at week-24. [ Time Frame: 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health & Science University, Department of DermatologyPortlandOregon97239
Amanda Mundy
[email protected]
503-494-6009
Alex Ortega Loayza, MD, MCR (PRINCIPAL_INVESTIGATOR)

Find similar trials in Portland, OR

By research site
Oregon Health & Science University, Department of Dermatology· Portland, OR

Related Studies